Chronic Cough Market Report 2025

The chronic cough market size has grown strongly in recent years. It will grow from $8.22 billion in 2024 to $8.9 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to prevalence of underlying respiratory conditions, environmental factors and air pollution, smoking and tobacco use, respiratory infections, allergies and environmental sensitivities.

The chronic cough market size is expected to see strong growth in the next few years. It will grow to $12.89 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to emerging therapies targeting specific pathways, increasing understanding of reflux-related cough, global efforts in smoking cessation, environmental and occupational health policies. Major trends in the forecast period include advancements in diagnostic technologies, patient-centric approaches, therapeutic innovations in neurogenic cough, telehealth for chronic cough management, research on central sensitization.

The surge in the prevalence of cough incidents is anticipated to drive the expansion of the chronic cough market in the foreseeable future. Coughing is a natural reflex that expels irritants or foreign substances from the airways, and when it persists for a duration exceeding eight weeks, it is termed as chronic. The increase in overall cough instances directly correlates with the rise in chronic cough cases. For example, as per March 2022 data from Florida Health, the US reported a total of 80 cases in 2021, marking an incidence of 41 and 1.4 per 100,000 individuals for cough and pertussis cases, respectively. Similarly, findings from the Statens Serum Institut in Denmark revealed a 41% increase in pertussis cases from November 2022 to April 2023 compared to the previous year. This escalating prevalence of cough-related conditions, notably pertussis, is a driving force behind the chronic cough market's growth.

The rising prevalence of smoking and tobacco use is projected to drive the growth of the chronic cough market in the future. Smoking involves burning a substance, usually tobacco, and inhaling or absorbing the resulting smoke into the bloodstream. This practice irritates the airways, contributes to chronic bronchitis, increases mucus production, diminishes lung function, weakens the immune system, interferes with the cough reflex, and raises the risk of lung cancer. For example, in September 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based national public health agency, reported that in 2022, 49.2 million adults (19.8%) in the U.S. - nearly 1 in 5 - indicated current use of tobacco products. Therefore, the growing prevalence of smoking and tobacco consumption is driving the expansion of the chronic cough market.

Major companies in the chronic cough market are focusing on developing innovative products like biosimilars to enhance their market position. Biosimilars are used to treat conditions such as cancer, autoimmune diseases, and diabetes, providing cost-effective alternatives to existing biologics. For example, in July 2024, Sandoz, a Switzerland-based pharmaceutical company, launched its biosimilar Pyzchiva (ustekinumab) across Europe, aimed at treating chronic inflammatory diseases like plaque psoriasis, psoriatic arthritis, and Crohn's disease. This biosimilar is particularly noteworthy as it is the first of its kind available in Europe with all strengths of the reference medicine, including the initiation dose for Crohn's disease. Developed in collaboration with Samsung Bioepis, Sandoz intends to improve access to effective treatments for millions affected by these conditions. The launch underscores Sandoz's commitment to offering affordable healthcare solutions and enhancing the quality of life for patients throughout Europe.

Leading enterprises in the chronic cough sector are emphasizing technologically advanced products such as cough detectors to drive market growth. Cough detection entails the identification and categorization of cough sounds using cutting-edge technologies such as artificial intelligence (AI) and machine learning. For instance, in May 2023, Hyfe Inc., a US-based company specializing in acoustic epidemiology with a focus on analyzing health sounds, particularly coughs, introduced a digital therapeutic. This innovative digital therapeutic aims to improve patients' lives by providing comprehensive care for chronic cough sufferers. Leveraging Hyfe's expertise in cough monitoring and its extensive database of over 700 million sounds, this digital therapy offers an end-to-end solution for managing coughs. By integrating speech therapy for cough treatment and suppression alongside breathing exercises accessible via mobile devices, this digital therapeutic addresses the needs of chronic cough patients.

In September 2022, the US-based biopharmaceutical company Pfizer Inc. successfully acquired the ASX-listed digital health startup ResApp Health for $115 million. This strategic acquisition was undertaken by Pfizer to strengthen its product portfolio and extend its footprint in key healthcare technology domains. ResApp is a smartphone application known for analyzing coughing patterns, accurately identifying respiratory conditions such as asthma, pneumonia, bronchiolitis, croup, and chronic obstructive pulmonary disease (COPD). ResApp Health, headquartered in Australia, is a healthcare solutions company that specializes in the management of chronic cough. This acquisition reflects Pfizer's commitment to leveraging innovative digital health solutions for enhanced healthcare offerings.

Major companies operating in the chronic cough market include Tris Pharma Inc., Pfizer Inc., Johnson & Johnson Co, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Glaxo SmithKline Plc, Merck KGaA, Reckitt Benckiser Group plc, Glenmark Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., Mylan NV, Aurobindo Pharma Ltd., Cipla Limited, Apotex Inc., Hikma Pharmaceuticals Plc, Amneal Pharmaceuticals LLC, Mount Sinai Health System, Biocon Ltd., BELLUS Health Inc., Trevi Therapeutics Inc., Sun Pharmaceutical Industries Ltd., NeRRe Therapeutics Ltd.

North America was the largest region in the chronic cough market in 2024. The regions covered in the chronic cough market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic cough market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic cough is characterized by persistent coughing lasting eight weeks or more, often indicative of an underlying condition such as asthma, allergies, or respiratory infections.

The primary drug classes for chronic cough include antihistamines, corticosteroids, decongestants, combination drugs, antibiotics, acid blockers, and others. Antihistamines are medications designed to address allergies by counteracting the physiological effects of histamines. These drugs can be administered through various routes, including oral, inhalational, injectable, and others, catering to settings such as hospitals, homecare, specialty centers, and more. Distribution channels for chronic cough medications encompass hospital pharmacies, online pharmacies, and retail pharmacies.

The chronic cough market research report is one of a series of new reports that provides chronic cough market statistics, including chronic cough industry global market size, regional shares, competitors with a chronic cough market share, detailed chronic cough market segments, market trends and opportunities, and any further data you may need to thrive in the chronic cough industry. This chronic cough market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic cough market consists of revenues earned by entities by providing services such as chest X-ray or CT scan services, lung function tests, and sputum culture. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic cough market also includes sales of cough suppressants, expectorants, inhalers, and allergy medications which are used in providing the services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.